Wild Week of Rotation: Sector Performance 2026…Update-2… 2/12/26…the AI effect!
Update-2 ..2/13....Disruption eases but way too early to call trends and pick tech stocks, but AMAT beat helps. AAPL down on memory chip squeeze. but VERTEX soars on Q4 2026 guided revenue to ~$13B 8-9% growth and pipeline. Green screen in large cap biopharma note Swiss: NVS and RHHBY near...
Large Cap Biopharmaceuticals: A Core Position for a Healthcare Portfolio…Update-5…hot stock EVMN
Update-5 2/10...Evommune (EVMN) up over 70% to the $29 level on Ph.2 a proof of concept trial for moderate to severe atopic dermatitis. The Company completed an IPO at $16/sh in NOV. '25 for proceeds of $172M. REGN was down on the announcement but presented 36 abstracts at the AAAI Allergy...
Healthcare Sector Review: Biopharma and Genomics are Strong
Healthcare Sector Review January 2026 This should be a good time to set markers in anticipation of earnings and after a sell-off in health insurance stocks as well as severe re-balancing in Technology and Precious metals trade. So with technology stocks hit by Microsoft the IGV is down 12.7%...
Update to our Trading Model for SMID Biotech Stocks 2026…Update-5 UNH down on 2026 outlook and Medicare Plans
Update-5 1/27/27...The XLV was down 1.68% today primarily because UNH took \about a 20% hit on their 2026 outlook and proposed Medicare reimbursement from CMMS. Given the Administration's posture to cut healthcare costs this should not be a surprise. Moreover the XLV currently has only about a...
Influenza Update-Influenza A (H3N2): How Bad is this Season?
FLU Season 2026-Declining but Widespread We saw several news updates on the 2025-26 Flu season and here is some of the latest information. This article from VOX is useful but if you are not a subscriber try a search mode.Why is this flu season so bad? If this cold and flu season seem especially...